Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction.

Journal of molecular medicine (Berlin, Germany) - 1 Dec 2022

Zhang Sainan, Li Mengyue, Tan Yilong, Zhang Juxuan, Liu Yixin, Jiang Wenbin, Li Xin, Qi Haitao, Tang Lefan, Ji Ran, Zhao Wenyuan, Gu Yunyan, Qi Lishuang

Abstract excerpt

There is no robust genomic signature to predict the prognosis of patients with early-stage lung adenocarcinoma (LUAD). It was known that clonal heterogeneity was closely associated to tumour progression and prognosis prediction. Herein, using stage I patients from The Cancer Genome Atlas, we identified the clonal/subclonal events of each gene and preselected a set of genes with prognosis-specific mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Transcriptome

Source

Identifiers

PMID: 36367565
DOI: 10.1007/s00109-022-02266-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction.PMID 36367565Read ↗

Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.Semantic proximity Read ↗

Lung adenocarcinoma WHO histological classes contain distinct immune cell profilesSemantic proximity Read ↗

Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.Semantic proximity Read ↗

A single-cell characterised signature integrating heterogeneity and microenvironment of lung adenocarcinoma for prognostic stratificationSemantic proximity Read ↗

Integration of multi-omics profiling reveals an epigenetic-based molecular classification of lung adenocarcinoma: implications for drug sensitivity and immunotherapy response predictionSemantic proximity Read ↗

Development of a novel prognostic score combining clinicopathologic variables, gene expression, and mutation profiles for lung adenocarcinoma.Semantic proximity Read ↗

Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.Semantic proximity Read ↗

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.Semantic proximity Read ↗

Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosisSemantic proximity Read ↗

Identification of lung adenocarcinoma subtypes and a prognostic signature based on activity changes of the hallmark and immunologic gene setsSemantic proximity Read ↗

Exploration of Tumor Mutation Burden Combined with Immune Infiltrates in the Prognosis of Lung AdenocarcinomaSemantic proximity Read ↗

An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.